Myotonic dystrophy
From Ganfyd
Myotonic dystrophy (dystrophia myotonica) is an autosomal dominant muscular dystrophy.
Contents |
Presentation
- Muscle stiffness (myotonia)(38%).[1]
- Myopathy
- Frontal balding
- Weakness of neck flexors
- A family history may aid the diagnosis
- Incidental - Haggard appearance, genetic screening
Common Features[2]
- Myotonia (90%)[3]
- Tongue, forearm, and hand.
- Muscular dystrophy
- Fatigue (44%)[4]
- Frontal balding
- Cataracts - a specific but not very sensitive sign i.e. many do not have it but if present with common features above diagnostic
- Infertility/Hypogonadism
- Muscle pain (20%)[5]
- Cardiac arrhythmias
- Hypogammaglobulinemia
Cause
Genetics as below causing failure of switch from embryonic to adult alternative splicing pattern of certain genes. CUG-binding protein 1 (CUG-BP1) and muscleblind-like 1 (MBNL1), the antagonistic regulators of alternative splicing of messenger RNA are disrupted.In the case of myotonia the muscle-specific chloride channel (CIC-1) remains embryonic[6]. In the case of insulin resistance, the insulin receptor has an embryonic gene splicing pattern.
Prevalence
- 2.2–5.5/100,000 in Europeans
- Less frequent in South-East Asians, rare in Polynesians, extremely rare in Central and Southern Africans. [7]
Types
Myotonic dystrophy-1 (DM1)
Presentation
Typically presents from 20 years onwards clinically, but there is a severe congenital form.
- Muscle dystrophy with onset distal muscles and only later proximal muscles (unlike other muscle dystrophies)
- Cardiac abnormalities
- Conduction deficits eg complete heart block
- Mitral valve prolapse
- Ventricular wall motion abnormality
- Exercise induced arrhythmias
- Cognitive deficits correlated with degree of CTG repeats over 1000.
- Sometimes [[hypersomnia], deafness, gastrointestinal hypermotility, ptosis and respiratory weakness.
- Often motor/sensory nerve involvement
Investigation
- EMG- most have myotonia
- Muscle biopsy non specific
- IgG levels low
- Blood glucose (5% diabetes)
- Gamma-glutamyltransferase (γGT) and creatine kinase (CK/CPK) may be increased.[8]
- Genetics - diagnostic
- Anticipation, mild through male line, much worse through female line
- Expanded CTG repeats (200-2000 plus) in 3-prime untranslated region of dystrophia myotonica protein kinase(DMPK) gene at 19q13.2-q13.3.
- Normal 5 to 30 CTG repeats
- ≥38 repeats usual cut off for disease
- Mild 50 to 80 CTG repeats
- Severe 2,000 or more CTG repeats
Prognosis
- Adults are at high risk of arrhythmia and sudden death
- Predictors of sudden death areNeeds citation:
- Severe ECG abnormalities
- Rhythm other than sinus
- PR interval ≥ 240msec
- QRS duration ≥ 120msec
- second or third degree heart block
- Atrial tachyarrhthmias
- Severe ECG abnormalities
- Predictors of sudden death areNeeds citation:
Myotonic dystrophy-2 (DM2)
- Myotonia onset usually third and fourth decade of life
- Muscular dystrophy usually mild proximal weakness fifth to seventh decade
No cognitive deficits, dysphagia, hypersomnia, deafness, gastrointestinal hypermotility, ptosis or respiratory weakness. Cataracts are rare.
- Genetics - diagnostic
- Expanded CCTG repeats in intron 1 of the zinc finger protein-9(ZNF9) gene with no good clinical correlation between number of repeats (75 to 11,000 ) and phenotype.
Treatment
Myotonia theoretically by increasing expression of MBNL1 Likely to be improved by systematic approach once diagnosis made as complex multi-system disease with potentially fatal or disabling complications open to intervention [9]
References
- ↑ Ford C, Kidd A, Hammond-Tooke G. Myotonic dystrophy in Otago, New Zealand. The New Zealand medical journal. 2006;119:U2145.original articlesubscription may be required
- ↑ Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60:657-64.
- ↑ Ford C, Kidd A, Hammond-Tooke G. Myotonic dystrophy in Otago, New Zealand. The New Zealand medical journal. 2006;119:U2145.original articlesubscription may be required
- ↑ Ford C, Kidd A, Hammond-Tooke G. Myotonic dystrophy in Otago, New Zealand. The New Zealand medical journal. 2006;119:U2145.original articlesubscription may be required
- ↑ Ford C, Kidd A, Hammond-Tooke G. Myotonic dystrophy in Otago, New Zealand. The New Zealand medical journal. 2006;119:U2145.original articlesubscription may be required
- ↑ Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, Thornton CA, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:11748-53. (Direct link – subscription may be required.)
- ↑ Ford C, Kidd A, Hammond-Tooke G. Myotonic dystrophy in Otago, New Zealand. The New Zealand medical journal. 2006;119:U2145.original articlesubscription may be required
- ↑ Schara U, Schoser BG. Myotonic dystrophies type 1 and 2: a summary on current aspects. Seminars in pediatric neurology. 2006;13:71-9. (Direct link – subscription may be required.)
- ↑ Ford C, Kidd A, Hammond-Tooke G. Myotonic dystrophy in Otago, New Zealand. The New Zealand medical journal. 2006;119:U2145.original articlesubscription may be required

